PTK2 and neoplasm: Despite the limited therapeutic effects of FAK or SFK inhibitors as monotherapies, the FAK/SFK axis is evidently a critical signaling pathway through which tumor cells recover malignant phenotypes following treatment with other antitumor agents.30 Therefore, FAK and SFKs are potential targets for combination therapy.